Daxor Corporation (DXR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Michael Richard Feldschuh
|
Chairman, President & CEO | 100.92k | -- | 1969 |
|
Mr. Robert J. Michel CPA, M.B.A.
|
CFO, Chief Compliance Officer & Corporate Secretary | 151.39k | -- | 1957 |
|
Mr. Jonathan Adam Feldschuh
|
Chief Scientific Officer & Director | 151.39k | -- | 1965 |
|
Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H.
|
Chief Medical Officer | 299.48k | -- | 1970 |
|
Ms. Linda Cooper
|
Vice President of Development & Operations | -- | -- | -- |
|
Ms. Kathryn A. Kornafel
|
Senior VP of Marketing & Commercial Development | -- | -- | -- |
|
Ms. Annette Plishka B.S.N.
|
Senior Vice President of Commercialization | -- | -- | -- |
Daxor Corporation
- Sector:
- Healthcare
- Industry: Medical Instruments & Supplies
Description
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
October 9, 2026 at 12:00 AM UTC
40-8F-2/A: Initial application for de-registration pursuant to Investment Company Act Rule 0-2
September 24, 2026 at 12:00 AM UTC
N-CEN/A: Annual Report for Registered Investment Companies
September 4, 2026 at 12:00 AM UTC
40-8F-2/A: Initial application for de-registration pursuant to Investment Company Act Rule 0-2
August 31, 2026 at 12:00 AM UTC
N-PX: Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
June 17, 2026 at 12:00 AM UTC
40-8F-2/A: Initial application for de-registration pursuant to Investment Company Act Rule 0-2
May 21, 2026 at 12:00 AM UTC
40-8F-2/A: Initial application for de-registration pursuant to Investment Company Act Rule 0-2
May 11, 2026 at 12:00 AM UTC
40-17F2: Initial certificate of accounting of securities and similar investments in the custody of management investment companies filed pursuant to Rule 17f-2 of the Investment Company Act of 1940 filed on Form N-17F-2
May 6, 2026 at 12:00 AM UTC
40-17F2: Initial certificate of accounting of securities and similar investments in the custody of management investment companies filed pursuant to Rule 17f-2 of the Investment Company Act of 1940 filed on Form N-17F-2
